HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henkel entering U.S. skin, hair care mass market with $93 mil. Dep buy.

This article was originally published in The Rose Sheet

Executive Summary

HENKEL's $93 MIL. DEP ACQUISITION IS 14.5 TIMES OPERATING PROFIT of $6.4 mil. in FY 1997 (ended July 31). By comparison, Carson's recent Johnson Products buy was for 9.1 times 1997 operating profit ("The Rose Sheet" June 22, p. 1). Under an agreement reached July 14, Dusseldorf, Germany-based Henkel will pay a 31% premium to Dep Corp.'s stock price at $5.25 a share for 6.9 mil. outstanding shares of common stock based on Dep's July 13 closing price of $4. The Berglass family owns approximately one-third of Dep common stock, worth more than $12 mil. at the $5.25 per share price. During a second phase of the merger, Henkel will acquire any shares not purchased in the first round for the same price. The deal is expected to commence July 20 and close within the quarter.

You may also be interested in...



Dep Styling Gel Extensions Include Anti-Dandruff Formula

Schwarzkopf & Dep will launch an anti-dandruff styling gel with active ingredient zinc pyrithione as one of four additions to the Dep line planned for January.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel